Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis’ RAD001 Doubles Progression-Free Survival in Advanced Renal Cancer Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

Median PFS was 4 months with everolimus, versus 1.9 months with placebo.

You may also be interested in...



Antisoma Advances AS1411 Aptamer In Kidney Cancer

Renal tumors and acute myeloma will serve as launch pad for trials in a range of solid and blood cancers.

Antisoma Advances AS1411 Aptamer In Kidney Cancer

Renal tumors and acute myeloma will serve as launch pad for trials in a range of solid and blood cancers.

Good Results Stop Novartis’ Phase III Everolimus Trial

Oral mTOR inhibitor could beat Wyeth’s IV Torisel in kidney cancer, Novartis exec tells “The Pink Sheet” DAILY.

Topics

UsernamePublicRestriction

Register

ID020288

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel